Table 2.

Association between ctDNA detection and clinical features in patients with LMS.

	ctDNA positive	ctDNA negative
Characteristic	N = 48	N = 50	P value
Age (mean)	60	59.1
≥65 years	19 (40%)	16 (32%)	0.72
<65 years	29 (60%)	34 (68%)
Sex
Male	17 (35%)	18 (36%)	0.95
Female	31 (65%)	32 (64%)
Number of sites at entry
>5 sites	35 (73%)	18 (36%)	<0.001
<5 sites	13 (27%)	32 (64%)
Tumor size
≥10 cm	36 (75%)	14 (28%)	<0.001
<10 cm	12 (25%)	36 (72%)
Stage
I–II	9 (19%)	15 (30%)	0.24
III–IV	39 (81%)	33 (66%)
Grade
Low/intermediate grade	18 (38%)	11 (22%)	0.09
High grade	30 (62%)	39 (78%)
Primary tumor location
Extremity	5 (10%)	13 (26%)	0.07
Other	43 (90%)	37 (74%)
Treatment
Doxorubicin	19 (40%)	22 (44%)	0.66
Doxorubicin + evofosfamide	29 (60%)	28 (56%)
Previous RT
Yes	9 (19%)	18 (36%)	0.06
No	39 (81%)	32 (64%)
Extent of disease
Locally advanced	1 (2%)	2 (4%)	1
Distant metastatic	47 (98%)	48 (96%)

Abbreviation: RT, radiotherapy.